نتایج جستجو برای: non small cell lung cancer nsclc
تعداد نتایج: 4070744 فیلتر نتایج به سال:
Lung cancer is the leading cause of cancer mortality in the world. Although some advances in lung cancer therapy have been made, patient survival is still poor. The platelet-derived growth factor receptors (PDGFRs) and their ligands play critical roles in the regulation of many cancer cell processes, including cell survival and cell motility. Herein, we investigate the anticancer activities of ...
Previous studies show inconsistent effect estimates for the efficacy of Endostar in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy. Therefore, this meta-analysis aimed to determine the effectiveness and safety on the basis of data obtained from available randomized controlled trials (RTCs). We find relevant articles reporting the use of Endostar combined ...
Purpose: Lung adenocarcinoma and lung squamous cell carcinoma (SCC) are the most common non–small cell lung cancer (NSCLC) subtypes. This study was designed to determine whether reduced expression of TGFb type II receptor (TGFbRII) promotes lung adenocarcinoma and SCC
Background: Lung cancer is the leading cause of cancer-related deaths, accounting for 1.8 million deaths (18%). Nearly 80%-85% lung cases are non-small cell cancers (NSCLC). One most frequent genetic mutations in NSCLC Kirsten Rat Sarcoma Oncogene Homolog (KRAS) gene mutation. In recent years, autophagy has drawn substantial attention as a potential pathway that can be targeted driven by KRAS m...
Lung cancer is the leading cause of cancer-related death in the world (Jemal et al., 2009). Non-small cell lung cancer (NSCLC) accounts for more than 80% percent of all cases of lung cancer. Surgery, radiotherapy and chemotherapy remain the three main regimens for the treatment of NSCLC. Over the past few years, molecular targeted agents, especially the EGFR inhibitors, have expanded the spectr...
Reports of pembrolizumab-induced lichen planus and eruptive keratoacanthomas are limited in the literature. Here, we describe unique concurrence both a patient who received pembrolizumab for non-small cell lung cancer (NSCLC). Although several therapies have been proposed, show that can be controlled with conservative management topical corticosteroids intralesional corticosteroids, respectivel...
MiR-195 suppresses tumor growth and is associated with better survival outcomes in several malignancies including non-small cell lung cancer (NSCLC). Our previous study showed high miR-195 plasma levels associated with favorable overall survival of non-smoking women with lung adenocarcinoma. To further elucidate role of miR-195 in NSCLC, we conducted in vitro experiment as well as clinical stud...
Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing more than 80% of lung cancer diagnoses. Five-year survival remains at 15%, but new strategies for prevention, early detection, and treatment may improve survival rates. This article provides an overview of updates in NSCLC, with an empha...
Background: Lazertinib is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to overcome EGFR T790M mutation. Currently, lazertinib approved for usage in the acquired mutation population based on promising clinical and safety profiles. In this study, we evaluated outcomes of mutated non-small cell lung cancer (NSCLC) patients real-world setting.
Alterations of Eph receptor tyrosine kinases are frequent events in human cancers. Genetic variations of EPHB6 have been described but the functional outcome of these alterations is unknown. The current study was conducted to screen for the occurrence and to identify functional consequences of EPHB6 mutations in non-small cell lung cancer. Here, we sequenced the entire coding region of EPHB6 in...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید